Clinical Trial Update: Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing a rivaroxaban-based strategy to an antiplatelet-based strategy after transcatheter aortic valve replacement (TAVR) to prevent leaflet th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Valve Stenosis
• Cardiovascular Diseases

Drugs mentioned

• antiplatelet-based strategy
• rivaroxaban-based strategy (rivaroxaban)

Snippet

Sponsor: ECRI bv | Conditions: Aortic Valve Stenosis, Cardiovascular Diseases | Phase 3 | Status: COMPLETED | Results posted: 2020-01-18